Laborie Medical Technologies announced today that it acquired an exclusive license to the Optilume urethral drug-coated balloon (DCB).
Portsmouth, New Hampshire-based Laborie purchased a perpetual, exclusive license to Optilume — developed by Urotronic — following FDA approval in December 2021. The DCB platform received CE mark approval for use in male anterior urethral strictures in 2020.
Get the full story at our sister site, Drug Delivery Business News.
Laborie Medical Technologies announced that it acquired Pelvalon and its Eclipse non-surgical device for treating fecal incontinence.
Redwood City, California-based Pelvalon designed the FDA-cleared Eclipse system as a patient-controlled device for women suffering from fecal incontinence, according to a news release.
Portsmouth, N.H.-based Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).
Financial terms for the acquisition were not disclosed.
“Laborie’s mission every day is to operate as a world-class specialist medical company making and advancing technologies that preserve and restore human dignity,” Laborie president & CEO Michael Frazzette said in the release. “Our mission is well served by the addition of Eclipse to help pa…